Fractyl Health to Present Landmark Updates on Revita® and Rejuva® Programs at the 83rd American Diabetes Association

LEXINGTON, Mass.–(BUSINESS WIRE)– #diabetesawareness–Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcoming 83rd Scientific Sessions of the American Diabetes Association, happening June 23-26, 2023, in San Diego, CA, and virtually. Fractyl Health will present clinical and preclinical updates on its Revita® and Rejuva® programs, respectively. The first presentation, “Glycemic Improvem
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks